- References (1)
- Inventor Info
|Antigen/Gene or Protein Targets||Tristetraprolin (TTP)|
|Parental Line||CT26 ATCC-CRL-2638|
|Relevance||CRISPR/Cas tristetraprolin (TTP) Knock-out KRAS mutant colon carcinoma cell line. In some immunoresistant tumours, PD-L1 expression is upregulated by RAS activation. Via the MEK pathway, the MK2 kinase phosporylates and inhibits TTP, which negatively regulates PD-L1 expression. PD-L1 is a therapeutic target to check the immune evasion mechanism of some cancers.|
|Production Details||CRISPR/Cas TTP Knock-out KRAS mutant colon carcinoma cell line.Knock Out of functional TTP was confirmed by Western blot. CompleteZfp36 allele disruption was confirmed by TOPO-TA cloning followed bysequencing.Mouse Zfp36 was targeted with gRNA sequenceGTCATGGCTCATCGACTGGAGG, using U6gRNA-Cas9-2A-GFP|
|Research Area||Cancer, Cell Cycle, Cell Signaling & Signal Transduction|
|Recommended Growing Conditions||RPMI-1640 + 10% FCS. Subculture split ratio of 1:4 to 1:10 every 2-3 days.|
CRISPR edited CT26 cells.
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.
This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
There are 1 reference entries for this reagent.View All References
Add an inventor